Template-driven chain shuffeling
Goal: Generation of an entirely novel, fully human antibody with similar or improved characteristics.
Principle: In a first step, the non-human VH domain is cloned into YUMAB® library vectors containing the full human VL repertoire. Vice versa, the non-human VL domain is cloned into YUMAB® library vectors that contain the full human VH repertoire. Since only one chain is replaced at a time, most antibodies from these hybrid libraries bind to the same or a similar epitope as the non-human antibody template. Subsequently, hybrid antibodies against the target structure are selected in-vitro.
In a second step, the human VH and VL domains of the selected antibodies are isolated and shuffled with each other, generating a new library of fully human antibodies. Again, most antibodies bind to the same or similar epitope as the non-human template. After a final antibody discovery against the target structure, the fully human antibodies are sequence analyzed, functionally tested and compared to the non-human antibody.
- Novel, fully human antibody sequences (no CDR related IP issues)
- Same or similar epitope
- Different or improved functional properties